4.8 Article

MicroRNA-211 Enhances the Oncogenicity of Carcinogen-Induced Oral Carcinoma by Repressing TCF12 and Increasing Antioxidant Activity

Journal

CANCER RESEARCH
Volume 76, Issue 16, Pages 4872-4886

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-15-1664

Keywords

-

Categories

Ask authors/readers for more resources

miR-211 expression in human oral squamous cell carcinoma (OSCC) has been implicated in poor patient survival. To investigate the oncogenic roles of miR-211, we generated K14-EGFP-miR-211 transgenic mice tagged with GFP. Induction of oral carcinogenesis in transgenic mice using 4-nitroquinoline 1-oxide (4NQO) resulted in more extensive and severe tongue tumorigenesis compared with control animals. We found that 4NQO and arecoline upregulated miR-211 expression in OSCC cells. In silico and experimental evidence further revealed that miR-211 directly targeted transcription factor 12 (TCF12), which mediated suppressor activities in OSCC cells and was drastically downregulated in tumor tissues. We used GeneChip analysis and bioinformatic algorithms to identify transcriptional targets of TCF12 and confirmed through reporter and ChIP assays that family with sequence similarity 213, member A (FAM213A), a peroxiredoxin-like antioxidative protein, was repressed transcriptionally by TCF12. FAM213A silencing in OSCC cells diminished oncogenic activity, reduced the ALDH1-positive cell population, and increased reactive oxygen species. TCF12 and FAM213A expression was correlated inversely in head and neck carcinoma samples according to The Cancer Genome Atlas. OSCC patients bearing tumors with high FAM213A expression tended to have worse survival. Furthermore, 4NQO treatment downregulated TCF12 and upregulated FAM213A by modulating miR-211 both in vitro and in vivo. Overall, our findings develop a mouse model that recapitulates the molecular and histopathologic alterations of human OSCC pathogenesis and highlight a new miRNA-mediated oncogenic mechanism. (C) 2016 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL

Ronald Tutrone, Michael J. Donovan, Phillipp Torkler, Vasisht Tadigotla, Tom McLain, Mikkel Noerholm, Johan Skog, James McKiernan

PROSTATE CANCER AND PROSTATIC DISEASES (2020)

Article Urology & Nephrology

A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy

James McKiernan, Mikkel Noerholm, Vasisht Tadigotla, Sonia Kumar, Phillipp Torkler, Grannum Sant, Jason Alter, Michael J. Donovan, Johan Skog

BMC UROLOGY (2020)

Review Oncology

Exosome-based liquid biopsies in cancer: opportunities and challenges

W. Yu, J. Hurley, D. Roberts, S. K. Chakrabortty, D. Enderle, M. Noerholm, X. O. Breakefield, J. K. Skog

Summary: Liquid biopsy in cancer research has seen significant progress, with efforts focused on utilizing circulating tumor cells, circulating tumor DNA, and extracellular vesicles like exosomes. Exosomes, as part of the intercellular communication system, carry tumor-derived materials and can serve as stable biomarkers for early detection and monitoring of cancer.

ANNALS OF ONCOLOGY (2021)

Article Urology & Nephrology

Discovery and Validation of a Urinary Exosome mRNA Signature for the Diagnosis of Human Kidney Transplant Rejection

Rania El Fekih, James Hurley, Vasisht Tadigotla, Areej Alghamdi, Anand Srivastava, Christine Coticchia, John Choi, Hazim Allos, Karim Yatim, Juliano Alhaddad, Siawosh Eskandari, Philip Chu, Albana B. Mihali, Isadora T. Lape, Mauricio P. Lima Filho, Bruno T. Aoyama, Anil Chandraker, Kassem Safa, James F. Markmann, Leonardo V. Riella, Richard N. Formica, Johan Skog, Jamil R. Azzi

Summary: The study demonstrates that urinary exosomal mRNA signatures are a powerful and noninvasive tool for screening kidney allograft rejection, with high predictive performance. The signatures can differentiate between different types of rejection and assist clinicians in therapeutic decision making.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Article Oncology

Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies

Erik Margolis, Gordon Brown, Alan Partin, Ballentine Carter, James McKiernan, Ronald Tutrone, Phillipp Torkler, Christian Fischer, Vasisht Tadigotla, Mikkel Noerholm, Michael J. Donovan, Johan Skog

Summary: The EPI test is a reliable noninvasive method that can discriminate between high-grade prostate cancer, low-grade cancer, and benign diseases. By pooling data from three independent studies, it was found that the EPI test performs better in distinguishing between prostate cancer pathologies (GG1 and GG2 and above).

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Article Urology & Nephrology

Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome

Alexander Kretschmer, Ronald Tutrone, Jason Alter, Elena Berg, Christian Fischer, Sonia Kumar, Phillipp Torkler, Vasisht Tadigotla, Michael Donovan, Grannum Sant, Johan Skog, Mikkel Noerholm

Summary: The study found that the EPI urine biomarker outperformed multivariate risk calculators in a group of pre-biopsy men. The EPI score was associated with low-risk pathology post-RP, with potential implications on AS decisions.

WORLD JOURNAL OF UROLOGY (2022)

Article Multidisciplinary Sciences

A SARS-CoV-2 antigen rapid diagnostic test for resource limited settings

Erica Frew, Douglas Roberts, Shelly Barry, Matthew Holden, Amanda Restell Mand, Emily Mitsock, Enqing Tan, Wei Yu, Johan Skog

Summary: To address the challenges posed by the novel coronavirus, a cost-effective and rapid SARS-CoV-2 antigen test has been developed, capable of identifying the presence of the virus in patient anterior nares swab samples with high sensitivity and no requirement for equipment or laboratory infrastructure.

SCIENTIFIC REPORTS (2021)

Article Multidisciplinary Sciences

Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy

Alexander Kretschmer, Holger Kajau, Eric Margolis, Ronald Tutrone, Tobias Grimm, Matthias Trottmann, Christian Stief, Georg Stoll, Christian A. Fischer, Claudia Flinspach, Anja Albrecht, Lisa Meyer, Tina Priewasser, Daniel Enderle, Romy Mueller, Phillipp Torkler, Jason Alter, Johan Skog, Mikkel Noerholm

Summary: Improved risk stratification of patients suspected of prostate cancer prior to biopsy is a clinical need. The non-invasive urine test EPI-CE utilizes RNA from exosomes to provide a risk score for high grade prostate cancer. In a clinical validation study, EPI-CE demonstrated superior performance compared to commonly used risk calculators, providing better risk assessment for patients suspected of prostate cancer.

SCIENTIFIC REPORTS (2022)

Article Multidisciplinary Sciences

Exosome based analysis for Space Associated Neuro-Ocular Syndrome and health risks in space exploration

Sudipto K. Chakrabortty, Yevgenia L. Khodor, Robert R. Kitchen, Dulaney L. Miller, Kailey M. Babcock, Kyle S. Manning, Steven P. Lang, Vasisht Tadigotla, Wei Yu, Eric Bershad, Johan Skog, Susana Zanello

Summary: Molecular profiling is important in space exploration for understanding the effects of environmental exposures on human health and performance. A novel exosome-based platform has been developed for profiling biological processes in body fluids, which has diagnostic applications and can be used to study Space Associated Neuro-Ocular Syndrome and monitor patients with impaired cerebrospinal fluid drainage or elevated intracranial pressure.

NPJ MICROGRAVITY (2022)

Letter Dermatology

Improved Sensitivity in BRAFV600E Detection in Combined Tissue and Extracellular Vesicle-Based Liquid Biopsy in Melanoma

Susana Garcia-Silva, Cristina Vico-Alonso, Lisa Meyer, Daniel Enderle, J. Aquiles Sanchez, Maria del Mar Onteniente, Mikkel Noerholm, Johan Skog, Jose-Luis Rodriguez-Peralto, Pablo-Luis Ortiz-Romero, Hector Peinado

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)

Article Oncology

ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer - an interim analysis

Ronald Tutrone, Ben Lowentritt, Brian Neuman, Michael J. J. Donovan, Elliot Hallmark, T. Jeffrey Cole, Yiyuan Yao, Claire Biesecker, Sonia Kumar, Vinita Verma, Grannum R. R. Sant, Jason Alter, Johan Skog

Summary: In the 5-year follow-up of the prostate biopsy Decision Impact Trial, patient outcomes were assessed based on a pre-biopsy ExoDx Prostate (EPI) score at 2.5 years. The results showed that patients with low-risk EPI scores had lower biopsy rates compared to those with high-risk EPI scores, while patients receiving standard of care had the same biopsy rates regardless of EPI score. Additionally, in the EPI arm, the time to first biopsy was longer for patients with low-risk EPI scores. This study demonstrates that the EPI test risk stratification identifies low-risk patients that are not found with the standard of care.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Article Oncology

Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer

Georgios Tsakonas, Vasisht Tadigotla, Sudipto K. Chakrabortty, Giuseppe Stragliotto, Dalin Chan, Rolf Lewensohn, Wei Yu, Johan K. Skog, Per Hydbring, Simon Ekman

Summary: In this study, the genetic analysis of cerebrospinal fluid (CSF) and its correlation to associated tumor compartments in non-small cell lung cancer (NSCLC) patients with brain metastases (BM) was investigated. The study found specific variants that could serve as targets for individually tailored therapies in NSCLC patients with BM.

LUNG CANCER (2023)

Meeting Abstract Oncology

Plasma Exosomal RNA Biomarkers of High-Risk Prostate Cancer

B. Spieler, Y. Khodor, S. Chakrabortty, C. Fischer, V. Tadigotla, R. Stoyanova, M. Abramowtiz, S. Punnen, A. Pollack, S. Yu, J. K. Skog, A. Dal Pra, S. M. Gaston

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Meeting Abstract Oncology

Biomarker screening for the early detection of prostate cancer using an exosomal-enrichment RNA liquid biopsy test.

Douglas Roberts, Emily Mitsock, Olubode Ogunlusi, Seth Yu, Johan Skog

JOURNAL OF CLINICAL ONCOLOGY (2020)

Article Oncology

Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma

Andrew S. Chi, Daniel P. Cahill, David A. Reardon, Patrick Y. Wen, Tom Mikkelsen, David M. Peereboom, Eric T. Wong, Elizabeth R. Gerstner, Jorg Dietrich, Scott R. Plotkin, Andrew D. Norden, Eudocia Q. Lee, Lakshmi Nayak, Shota Tanaka, Hiroaki Wakimoto, Nina Lelic, Mara V. Koerner, Lindsay K. Klofas, Mia S. Bertalan, Isabel C. Arrillaga-Romany, Rebecca A. Betensky, William T. Curry, Darrel R. Borger, Leonora Balaj, Robert R. Kitchen, Sudipto K. Chakrabortty, Michael D. Valentino, Johan Skog, Xandra O. Breakefield, A. John Iafrate, Tracy T. Batchelor

JCO PRECISION ONCOLOGY (2020)

No Data Available